We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Loss of Long Noncoding RNA Inhibits Breast Tumor Metastasis in Mouse Model

By LabMedica International staff writers
Posted on 05 Jan 2016
Print article
Image: Left panel: Micrograph of an undifferentiated breast tumor - densely packed with cancerous cells and with a high potential to spread. Right panel: Differentiated tumor following anti-Malat1 ASO treatment with cyst-like cells filled with fluid containing, among other things, milk proteins. Treated tumors were comparatively static with reduced metastatic activity (Photo courtesy of Spector Laboratory, Cold Spring Harbor Laboratory).
Image: Left panel: Micrograph of an undifferentiated breast tumor - densely packed with cancerous cells and with a high potential to spread. Right panel: Differentiated tumor following anti-Malat1 ASO treatment with cyst-like cells filled with fluid containing, among other things, milk proteins. Treated tumors were comparatively static with reduced metastatic activity (Photo courtesy of Spector Laboratory, Cold Spring Harbor Laboratory).
Blocking the activity of a single long noncoding RNA (lncRNA) in malignant breast cancer mouse models transformed aggressive cancers into slow growing cyst-like tumors and reversed the metastatic process by up to 70%.

Long noncoding RNAs (lncRNAs) are non-protein coding transcripts longer than 200 nucleotides. This somewhat arbitrary limit distinguishes lncRNAs from small regulatory RNAs such as microRNAs (miRNAs), short interfering RNAs (siRNAs), Piwi-interacting RNAs (piRNAs), small nucleolar RNAs (snoRNAs), and other short RNAs. LncRNAs have been found to be involved in numerous biological roles including imprinting, epigenetic gene regulation, cell cycle and apoptosis, and metastasis and prognosis in solid tumors. Most lncRNAs are expressed only in a few cells rather than whole tissues, or they are expressed at very low levels, making them difficult to study.

Malat1 (metastasis-associated lung adenocarcinoma transcript 1) is among the most abundant lncRNAs whose expression is altered in numerous cancers. Investigators at Cold Spring Harbor Laboratory (NY, USA) examined the role of Malat1 in cancer by either knocking it out—genetically engineering animals to lack the Malat1 gene—or with specific antisense oligonucleotides (ASO) that blocked Malat1 activity despite the presence of the active gene.

They reported in the December 23, 2015, online edition of the journal Genes & Development that genetic loss or systemic knockdown of Malat1 using antisense oligonucleotides in the MMTV (mouse mammary tumor virus)-PyMT mouse mammary carcinoma model resulted in slower tumor growth accompanied by significant differentiation into cystic tumors and a reduction in metastasis by up to about 70%. The ASOs were developed in collaboration with the biotechnology firm Ionis Pharmaceuticals (Carlsbad, CA, USA).

Malat1 loss resulted in a reduction of branching morphogenesis in MMTV-PyMT- and Her2/neu-amplified tumor organoids, increased cell adhesion, and loss of migration. At the molecular level, Malat1 knockdown caused alterations in gene expression and changes in splicing patterns of genes involved in differentiation and pro-tumorigenic signaling pathways.

"We got an amazing result," said senior author Dr. David L. Spector, head of the gene regulation and cell proliferation program at Cold Spring Harbor Laboratory. "By removing Malat1—this one, single long noncoding RNA—we made a dramatic impact on the primary breast tumors in these mice. The tumors took on a wholly new character. Aggressive breast cancer tumors differentiated and took on cyst-like characteristics. They filled with fluid, which contained various proteins including milk proteins, demonstrating that some of the tumor cells had differentiated. Just as important, in these mice lacking Malat1, there was nearly no metastasis."

"We are very pleased and excited by this result," said Dr. Spector, "because it suggests that these metastatic tumors have a dependency on Malat1—they cannot thrive without it. And very importantly, targeting Malat1 should not have a deleterious effect on any normal cells. At least in this mouse model normal, noncancerous cells do not seem to care a bit if they have Malat1 or not. Only the cancer cells seem to require it."

Related Links:

Cold Spring Harbor Laboratory
Ionis Pharmaceuticals 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.